{
    "nctId": "NCT00899548",
    "briefTitle": "DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer",
    "officialTitle": "DNA Methylation in Serum as a Predictive Marker of Progression and Survival Following Systemic Therapy in Patients With Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 182,
    "primaryOutcomeMeasure": "Progression-free Survival in Patients With a High vs. Low Cumulative Methylation Index (CMI) Value",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Meets 1 of the following criteria:\n\n  * Histologically and/or cytologically confirmed stage IV adenocarcinoma of the breast (patient)\n  * No diagnosis of an abnormal breast biopsy (including atypical ductal or lobular hyperplasia), or new diagnosis of breast cancer or breast cancer recurrence within the past five years (healthy participant)\n* Evidence of disease progression AND initiating a new systemic treatment regimen with trastuzumab (Herceptin\u00ae), chemotherapy, endocrine therapy, or investigational agent(s) (patient)\n\n  * Treatment may be given as a single agent or in combination\n* Measurable or evaluable disease (patient)\n\n  * Measurable disease is defined as \u2265 1 measurable lesion identified by RECIST criteria\n  * Patients with evaluable disease only must have \u2265 1 tumor marker (e.g., carcinoembryonic antigen, CA 27-29, or CA 15-3) above normal level\n* Treated brain metastases (surgery or radiation therapy) allowed provided patient has evidence of disease stability or presence of other site(s) of measurable or evaluable disease (patient)\n\n  * No leptomeningeal disease\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Female\n* Menopausal status not specified\n* ECOG performance status 0-2\n* No known cancer within the past 5 years other than basal cell or squamous cell carcinoma of the skin and/or adequately treated cervical cancer (healthy participant)\n* Not pregnant or nursing\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Prior therapy in the preoperative, adjuvant, and/or metastatic setting allowed\n\n  * Any number of prior regimens in any setting allowed\n* No prior radiation therapy to the only site of disease unless there is evidence of post-radiation disease progression\n* No selective estrogen receptor modulator or aromatase inhibitor for breast cancer prevention or therapy within the past 12 months (healthy participant)\n* Prior or concurrent use of raloxifene for osteopenia or osteoporosis therapy allowed (healthy participant)\n* Concurrent participation in another clinical trial, including one involving an investigational agent(s), allowed",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}